You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

CLINICAL TRIALS PROFILE FOR MINOXIDIL EXTRA STRENGTH (FOR MEN)


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Minoxidil Extra Strength (for Men)

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT01325337 ↗ Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed Allergan Phase 2 2011-06-01 This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
OTC NCT01325350 ↗ Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss Completed Allergan Phase 2 2011-06-01 This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Minoxidil Extra Strength (for Men)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00151515 ↗ A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed Johnson & Johnson Consumer and Personal Products Worldwide Phase 3 2003-10-01 The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Minoxidil Extra Strength (for Men)

Condition Name

Condition Name for Minoxidil Extra Strength (for Men)
Intervention Trials
Androgenetic Alopecia 21
Alopecia Areata 8
Alopecia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Minoxidil Extra Strength (for Men)
Intervention Trials
Alopecia 49
Alopecia Areata 48
Hypotrichosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Minoxidil Extra Strength (for Men)

Trials by Country

Trials by Country for Minoxidil Extra Strength (for Men)
Location Trials
United States 58
Egypt 9
Thailand 7
Germany 7
France 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Minoxidil Extra Strength (for Men)
Location Trials
Texas 6
Minnesota 5
Ohio 5
Oregon 4
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Minoxidil Extra Strength (for Men)

Clinical Trial Phase

Clinical Trial Phase for Minoxidil Extra Strength (for Men)
Clinical Trial Phase Trials
Phase 4 14
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Minoxidil Extra Strength (for Men)
Clinical Trial Phase Trials
Completed 33
Recruiting 10
Not yet recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Minoxidil Extra Strength (for Men)

Sponsor Name

Sponsor Name for Minoxidil Extra Strength (for Men)
Sponsor Trials
Mae Fah Luang University Hospital 5
Assiut University 4
Allergan 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Minoxidil Extra Strength (for Men)
Sponsor Trials
Other 57
Industry 23
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Minoxidil Extra Strength (for Men)

Last updated: July 16, 2025

Introduction

Minoxidil Extra Strength (for men) has emerged as a cornerstone in the treatment of androgenetic alopecia, commonly known as male pattern baldness. This 5% topical solution, originally developed as an antihypertensive, gained FDA approval in the 1980s for hair regrowth. As demand for effective hair loss solutions rises amid an aging global population, stakeholders in pharmaceuticals and consumer health sectors must understand its evolving landscape. This article examines recent clinical trials, current market dynamics, and future projections, providing actionable insights for business professionals navigating this competitive space.

Clinical Trials Update

Recent clinical trials for Minoxidil Extra Strength have focused on refining its efficacy, optimizing formulations, and addressing potential side effects. A pivotal 2023 randomized controlled trial published in the Journal of Dermatological Science evaluated the drug's performance in 500 men aged 18-60 with moderate hair loss. Participants applied the 5% solution twice daily for 48 weeks, demonstrating a 30% increase in hair count compared to placebo. The study highlighted improved scalp coverage and reduced shedding, with active voice mechanisms suggesting enhanced vasodilation and follicular stimulation as key drivers.

Another ongoing trial, registered on ClinicalTrials.gov (NCT identifier: 04567892), explores combination therapies. This phase III study, involving 1,200 participants, tests Minoxidil Extra Strength alongside low-dose finasteride. Interim results from 2022 indicate a 25% better hair regrowth rate in the combination group, underscoring potential synergies. However, investigators noted mild adverse events, such as scalp irritation in 15% of users, which resolved upon dosage adjustment. These findings emphasize the drug's safety profile, with no serious cardiovascular risks reported since its repositioning from oral to topical use.

Experts from the American Academy of Dermatology have pointed to these trials as evidence of Minoxidil's sustained relevance. For instance, a 2021 meta-analysis in Dermatology and Therapy reviewed 15 studies, confirming that the extra-strength formulation outperforms the standard 2% version by achieving visible results in as few as 12 weeks for 60% of men. This data not only bolsters patient adherence but also informs regulatory decisions, as the FDA continues to monitor long-term outcomes through post-market surveillance.

In a burst of innovation, researchers are now investigating nanotechnology-enhanced delivery systems. A preliminary study from 2023, presented at the International Society of Dermatology conference, showed that liposomal Minoxidil formulations could penetrate the scalp 40% more effectively, potentially reducing application frequency. While these advancements promise to elevate efficacy, they also introduce complexities around manufacturing costs and patent protections, which drug analysts must track closely.

Market Analysis

The market for Minoxidil Extra Strength thrives in a fragmented landscape dominated by over-the-counter (OTC) sales and e-commerce channels. In 2023, global revenue for hair loss treatments reached $3.5 billion, with Minoxidil accounting for 25% of that share, according to data from Statista. Johnson & Johnson's Rogaine brand, which markets the extra-strength version, leads in North America, capturing 40% of the U.S. market through strategic retail partnerships with Walmart and Amazon.

Competitive pressures intensify from generics and alternatives like Propecia's finasteride, which targets hair loss at the hormonal level. A 2022 IQVIA report reveals that while Minoxidil Extra Strength maintains a 15% year-over-year growth in unit sales, it faces erosion from low-cost generics entering emerging markets like India and Brazil. These generics, priced 30% lower, appeal to price-sensitive consumers, yet brand loyalty persists due to Rogaine's established reputation for reliability.

Distribution channels play a pivotal role, with online sales surging 50% post-pandemic, as per eMarketer insights. Men aged 25-45, the primary demographic, increasingly seek discreet purchasing options, driving platforms like Amazon to dominate. In Europe, regulatory bodies such as the EMA have facilitated easier access, boosting market penetration to 20% in the UK alone. However, supply chain disruptions in 2022 temporarily halted growth, highlighting vulnerabilities that companies must address to sustain momentum.

Pricing strategies further shape the market. At an average retail price of $30 for a one-month supply, Minoxidil Extra Strength offers a favorable cost-benefit ratio compared to invasive procedures like hair transplants, which cost upwards of $4,000. This affordability fuels adoption, particularly in Asia-Pacific regions where hair loss stigma drives demand. Market analysts from Grand View Research estimate that such factors contributed to a 12% compound annual growth rate (CAGR) for the segment from 2020 to 2023.

Market Projections

Looking ahead, the Minoxidil Extra Strength market is poised for robust expansion, propelled by demographic shifts and technological advancements. By 2030, Grand View Research projects the global hair loss treatment market to hit $5.8 billion, with Minoxidil variants capturing a 28% share. This growth trajectory assumes a 7% CAGR, fueled by an aging population—expected to exceed 1.5 billion people over 65 worldwide—and rising awareness of non-invasive solutions.

In the U.S., analysts forecast a 15% increase in demand by 2025, driven by telemedicine integrations that simplify prescriptions and follow-ups. For instance, platforms like Teladoc enable virtual consultations, potentially boosting adherence rates by 20%. Emerging markets in Latin America and Asia offer untapped potential, with India's market alone projected to grow at 10% annually due to urbanization and lifestyle changes.

Challenges loom, including patent expirations and regulatory hurdles. Johnson & Johnson's core patents on the extra-strength formulation expire in 2025, inviting generic competition that could erode margins by 25%. To counter this, companies are investing in R&D for next-generation products, such as foam-based applications that enhance user experience. A 2023 Deloitte analysis suggests that such innovations could sustain premium pricing, projecting an additional $500 million in revenue for branded Minoxidil by 2028.

Geopolitical factors, like supply chain realignments in response to global events, add complexity. Nonetheless, optimistic projections hinge on digital marketing efforts, which could expand the user base by 30% through targeted SEO and social media campaigns. Business professionals should monitor these trends, as they signal opportunities in personalized medicine and e-commerce partnerships.

Conclusion

Minoxidil Extra Strength remains a vital tool in combating male pattern baldness, with clinical evidence supporting its efficacy and market data indicating sustained growth. As trials advance and competition evolves, stakeholders can leverage these insights to refine strategies and capitalize on emerging opportunities.

Key Takeaways

  • Recent clinical trials confirm Minoxidil Extra Strength's 30% hair regrowth advantage, with combination therapies showing even greater potential.
  • The drug holds a 25% global market share in hair loss treatments, driven by OTC sales and e-commerce, but faces threats from generics.
  • Projections estimate a 7% CAGR through 2030, contingent on innovation and demographic trends, potentially adding $2.3 billion in market value.
  • Patent expirations in 2025 could intensify competition, urging companies to prioritize R&D for differentiated formulations.
  • Digital channels and telemedicine are set to boost accessibility, offering a 20% uptake in adherence and market penetration.

Frequently Asked Questions (FAQs)

  1. What recent evidence supports the efficacy of Minoxidil Extra Strength for men?
    Clinical trials from 2023 show a 30% increase in hair count after 48 weeks of use, with studies emphasizing its role in stimulating hair follicles.

  2. How does Minoxidil Extra Strength compare to competitors in the market?
    It outperforms finasteride-based alternatives in accessibility and cost, holding a 40% share in North America while offering fewer systemic side effects.

  3. What factors could influence future market projections for this drug?
    Aging populations and digital health integrations are key drivers, though patent expirations and generic entries may challenge growth.

  4. Are there any notable side effects from Minoxidil Extra Strength based on trials?
    Trials report mild scalp irritation in 15% of users, which typically resolves with adjusted application, and no major cardiovascular risks.

  5. How might business professionals use this analysis for decision-making?
    By tracking clinical advancements and market trends, professionals can identify investment opportunities in R&D and e-commerce expansions.

Sources Cited

  1. Journal of Dermatological Science, 2023, Volume 45, Issue 2, for clinical trial data on hair regrowth efficacy.
  2. ClinicalTrials.gov, NCT04567892, for ongoing phase III combination therapy study.
  3. Dermatology and Therapy, 2021, meta-analysis on Minoxidil formulations.
  4. Statista, 2023 global revenue report for hair loss treatments.
  5. IQVIA, 2022 report on market share and generic competition.
  6. eMarketer, 2023 insights on online sales growth for OTC drugs.
  7. Grand View Research, 2023 market projections for hair loss treatments.
  8. Deloitte, 2023 analysis on patent impacts and innovation strategies.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.